. 2009 Feb 18;2:17–27.

Table 1.

Selected randomized studies evaluating chemotherapy in patients with metastatic colorectal cancer

Author, year	Regimen	No of patients	RR (%)	Median PFS (months)	Median OS (months)
FU/FA versus combination with irinotecan
Saltz et al 2000⁹⁶	FU/FA	226	21	4.3	12.6
Saltz et al 2000⁹⁶	IFL	231	39^*	7.0^*	14.8^*
Douillard et al 2000⁹⁷	FU/FA	187	22	4.4	14.1
Douillard et al 2000⁹⁷	FOLFIRI	198	35^*	6.7^*	17.4^*
Köhne et al 2005⁹⁸	FU/FA	216	32	6.4	16.9
Köhne et al 2005⁹⁸	FUFIRI	214	54^*	8.5^*	20.1
5-FU/FA versus combination with oxaliplatin
de Gramont et al 2000⁹⁹	FU/FA	210	22	6.2	14.7
de Gramont et al 2000⁹⁹	FOLFOX	210	51^*	9.0^*	16.2
Giacchetti et al 2000¹⁰⁰	FU/FA	100	12	6.1	19.9
Giacchetti et al 2000¹⁰⁰	FOLFOX	100	34^*	8.7^*	19.4
Combination versus combination
Tournigand et al 2004¹¹	FOLFOX	111	54	10.9	20.6
Tournigand et al 2004¹¹	FOLFIRI	111	56	14.2	21.5
Goldberg et al 2004¹⁴	IFL	264	31	6.9	15.0
Goldberg et al 2004¹⁴	FOLFOX	267	45^*	8.7^*	19.5^*
Glimelius et al 2008¹²	FLIRI	281	35	9.4	19.4
Glimelius et al 2008¹²	FOLFIRI	286	49^*	9.0	19.0
Cassidy et al 2008¹³	XELOX	1017	47	8.0	19.8
Cassidy et al 2008¹³	FOLFOX	1017	48	8.5	19.6

Significant difference.

Abbreviations: FU/FA, 5-fluorouracil/folinic acid; RR, response rate; PFS, progression-free survival; OS, overall survival.